Sections
Buspar is the anti-anxiety drug I wish more people had heard of, mostly because it’s the answer to a lot of situations where the patient or the prescriber is reaching for a benzo without quite realizing there’s a middle option. It’s not perfect. It’s not as fast. It doesn’t have the same immediate relief profile as a Xanax tab does. But for a a real chunk of patients with generalized anxiety, it’s the right answer and almost nobody pitches it because almost nobody remembers it’s there.
If we’re being honest, the conversation about anxiety meds in most psychiatric visits has shrunk to “do you want an SSRI or a benzo.” Buspar sits in the slot in the middle of that conversation that nobody opens. That’s a fixable problem, and one of the more useful pieces of patient education a prescriber can do is to actually pitch the existence of the middle option.
What it does and what it doesn’t
Buspirone is a 5-HT1A partial agonist with some dopamine activity, which in plain language means it nudges a specific serotonin receptor in a slightly different direction than the SSRIs do, plus a little dopamine work on the side. Not an SSRI. Not a benzo. Not a beta blocker. Not anything else most patients have heard of. It’s been on the market since 1986 and is one of the few non-benzo anxiety drugs with a clean FDA approval for generalized anxiety disorder.
The mechanism is different enough from everything else that it doesn’t really fit into any of the families patients try to put their meds into, which is part of why it gets forgotten, and it’s also part of why it’s useful… it can be added to an SSRI without much interaction, it can be used alone, and it doesn’t carry the dependence and withdrawal baggage of the benzodiazepines (Xanax, Ativan, Klonopin, Valium, the whole sleep-and-anxiety class that has its own particular set of problems).
What Buspar won’t do is stop a panic attack. It is not an as-needed medication and it does not work in thirty minutes. If you take one Buspar tablet because you’re nervous about a meeting, nothing useful is going to happen, because the drug has to be in your system at a steady dose for two to four weeks before it starts doing anything, and full effect takes six to eight weeks, similar to an SSRI. This is why patients who get prescribed Buspar and aren’t told what to expect often abandon it… they take it for a week, decide it’s not doing anything, switch to something they think is working, which is a fixable communication problem, not a problem with the drug.
The dosing and the side effect profile
Standard starting dose is 7.5mg twice a day, titrated up to 15mg twice daily over a couple of weeks, with most patients ending up in the 30 to 60mg per day range divided BID or TID (twice or three times a day in doctor-speak). Yes, it’s dosed multiple times a day, which is annoying. There’s no once-daily extended-release version, which is unfortunate. Most patients tolerate the BID schedule fine, especially when paired with morning coffee and dinner, which is just a phone reminder away from being a non-issue.
Side effect profile is one of the cleanest in psychiatry. Some patients get dizziness, occasional headache, mild nausea in the first week or two. Most settle in fine. No sexual side effects to speak of, which is the part that matters for a a real chunk of guys deciding between this and an SSRI. No weight gain. No sedation. No cognitive effects, you don’t feel out of it. No withdrawal. The clean profile is most of why it’s a good drug for the right patient and most of why it’s underused, because nothing about the side effect picture grabs anyone’s attention.
Why it’s underused
Two reasons. First, it requires patient education that most rushed psychiatric visits don’t have time for. “Take this twice a day for six weeks and you’ll start to notice it, also it won’t work the way you might be expecting from how benzos work” is a paragraph that doesn’t fit in a fifteen-minute slot easily. Without that paragraph, the patient quits at week two and the drug gets a reputation for not working when actually it just didn’t get used long enough to show what it does.
Second, by the time most patients with generalized anxiety get to a psychiatrist, they’ve already tried an SSRI and either it worked or it didn’t. If it worked, no one switches them to Buspar. If it didn’t, the next move is often a second SSRI or an SNRI rather than a Buspar trial, partly out of habit, partly because the data on switching to Buspar after an SSRI failure isn’t as deep as the data on SSRI-to-SSRI or SSRI-to-SNRI moves. The drug ends up being a third or fourth move when it should sometimes be the second, and patients spend extra months on drugs that aren’t going to work before getting to one that might.
It also gets overlooked because benzos remain the fastest route to short-term relief, and a lot of prescribers, when they get a patient with severe anxiety in front of them, end up writing a small benzo prescription as a bridge. Sometimes that bridge becomes a year. Sometimes that year becomes a decade. Buspar is part of the answer to not doing that. Benzos have a narrow defensible niche and a lot of off-niche use, and any drug that lets the prescriber avoid widening the benzo niche unnecessarily is doing useful work.
When to pick it
Generalized anxiety disorder where the patient doesn’t tolerate or doesn’t want to be on an SSRI. Generalized anxiety where an SSRI has partial response and we want to augment without adding a second SSRI. Patients who specifically don’t want any of the SSRI side effects (sexual, weight, sleep). Patients who don’t want a benzo. Patients with a substance use history where benzos are particularly contraindicated, which is a significant subset of the patients who come in with anxiety as the presenting complaint and a drinking problem somewhere in the background.
It’s also a real consideration for older patients. The clean side effect profile, the lack of cognitive effects, the absence of the falls-and-fracture risk associated with benzos, all of that makes Buspar a friendlier drug for older-age anxiety than most of the alternatives. The 75-year-old with anxiety and a history of falls who’s also somehow ended up on Klonopin from a prescriber who should have known better is the patient where the Buspar conversation should have happened ten years earlier.
The benzo conversation, briefly, because it’s adjacent
Worth saying clearly that benzos are broadly a bad idea for ongoing anxiety treatment. They work, in the sense that they make the anxiety go away in thirty minutes. They also build tolerance fast, produce dependence within weeks of daily use, and the discontinuation profile when somebody’s been on them for a year or longer is genuinely rough, sometimes dangerous. Their defensible niche is narrow, short-term use for an acute crisis, occasional as-needed for flight anxiety or a procedure, that kind of thing. Buspar’s role is partly to make the case for not putting somebody on a daily benzo as the second move when an SSRI didn’t work, because the daily benzo path leads to a worse place than the daily Buspar path does. Any prescriber who pretends daily benzos are safe long-term is a damn liar.
The patient autonomy piece
If you want Buspar and you’ve heard the honest take that it takes weeks to work and is dosed twice a day, the answer is yes. If you want to try a benzo instead and you’ve heard the honest take about tolerance and dependence, the answer for short-term as-needed use is also often yes, with the conversation about what we’re going to do if as-needed becomes daily. Provider, not parent. Appointment isn’t mine. I hardly ever say no. The honest take is what I’m here for, the choice is yours.
The exception is the patient who comes in asking for a benzo with a substance use history that makes it actively dangerous. That’s the one where the conversation slows down and the disapproving yes might actually be a no, or a yes with a very narrow plan. The math on benzos in a patient with a drinking problem or an opioid history is different and the prescriber’s risk tolerance has to factor in.
What’s nice to hear
For the right patient, Buspar works. Six weeks of background dose, the background hum of anxiety drops to half, by week ten it’s mostly quiet most of the day. Still gets amped up in specific high-stakes situations but doesn’t hold for hours the way it used to. No sexual side effects. No weight gain. No sleep disruption. No sedation. The trade-off the patient was dreading turns out not to be necessary. That’s the case for the drug existing, and it’s the case for it being tried earlier in more patients than it currently is. Picture a guy with three years of sobriety, a daily generalized anxiety problem he’s been grinding through, who specifically can’t take a benzo because of his recovery and didn’t tolerate Zoloft because of the sexual side effects… Buspar at 20mg twice a day, four years in, still good, still sober, hasn’t been back except for refills. That’s the version of the underused drug being the right answer and would have been the right answer earlier in his sequence if anyone had pitched it sooner.
Buspar is the anti-anxiety drug I wish more people had heard of, because it’s the answer to situations where the patient or the prescriber is reaching for a benzo without realizing there’s a middle option.
Bottom line
Buspar isn’t going to stop a panic attack and it isn’t going to work in a week. For ongoing generalized anxiety where you want something cleaner than an SSRI and safer than a benzo, it’s a real option that mostly nobody talks about. If your prescriber hasn’t mentioned it and you’re looking at the next step, ask. Worst case, it doesn’t work for you and you move on. Best case, it does, and the trade-offs you were dreading turn out not to be necessary. Either way you’ll know more than you did when you walked in, which is what an appointment is for.
The drug isn’t sexy, isn’t on the marketing budget for any of the bigger players anymore, doesn’t get talked about on the internet because nothing dramatic happens on it. That’s another tick in the Buspar-is-better column for the right patient, where the lack of drama is the entire point. Anxiety that quietly drops to background level over a few weeks, no withdrawal to plan around, no sexual side effects to negotiate, no benzo-style tolerance creep. The boring drug doing the boring job is exactly what generalized anxiety treatment is supposed to look like.
Sources
- U.S. Food and Drug Administration. BuSpar (buspirone hydrochloride) Prescribing Information. NDA 018731. FDA; 2010 (buspirone generic no longer branded; most recent label). FDA label.
- Slee A, Nazareth I, Bondaronek P, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019;393(10173):768–777. PMID 30712879.
- Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–1366. PMID 29477251.
